CELLINK launches a real-time qPCR instrument

CELLINK has started reselling a qPCR instrument. The instrument uses a laboratory technique of molecular biology based on the polymerase chain reaction. It monitors the amplification of a targeted DNA molecule during the PCR (i.e., in real time).

qPCR is a proven and stable technology with numerous applications. It is commonly used for both diagnostic and basic research. Uses of the technique in the industry include the quantification of microbial load in foods, the detection of GMOs (genetically modified organisms) and the quantification and genotyping of human viral pathogens such as SARS-CoV-2. The unit includes dual channels and is open source, allowing users to use any kit to run their samples. It is designed as a high-quality, low-throughput qPCR cycler. The instrument is easy to use and runs a sample in 20-40 minutes. CELLINK wants to help provide scientists with the tools they need to make a difference and therefore offers this instrument at a low-cost point to help advance research related to the COVID-19 pandemic.

Contact sales@cellink.com for more information about the product.

For further information, please contact:

Erik Gatenholm, CEO                                                                 Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00                                       Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566                                               Phone (US): +1 (857) 332 2138

E-mail: eg@cellink.com                                                              E-mail: gd@cellink.com

About CELLINK

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: certifiedadviser@penser.se.